A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 30, 2017

Study Completion Date

October 30, 2017

Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
BIOLOGICAL

IMM-124E

IMM-124E

OTHER

Placebo

Matched placebo

Trial Locations (25)

2145

Westmead Hospital, Westmead

2750

The Nepean Hospital, Penrith

3004

The Alfred Hospital, Prahran

3050

Royal Melbourne Hospital, Parkville

3128

Box Hill Hospital, Box Hill

4102

Princess Alexandra Hospital, Woolloongabba

22908

University of Virginia Medical Centre, Charlottesville

23226

Bon Secours St Marys Hospital, Richmond

23298

Virginia Commonwealth University, Richmond

23602

Mary Immaculate Hospital, Newport News

27710

Duke Liver Centre, Durham

32610

University of Florida Hepatology Research at CTRB, Gainesville

44195

Cleveland Clinic, Cleveland

60611

Northwestern Memorial Hospital, Chicago

64131

Kansas City Research Institute, Kansas City

64239

Sourasky Medical Center (Ichilov), Tel Aviv

77030

Baylor St Lukes Medical Centre, Houston

78233

Pinnacle Clinical Research, Live Oak

78234

Brooke Army Medical Centre, Houston

80045

University of Colorado, Aurora

91911

eStudySite, Chula Vista

92103

University of California San Diego, San Diego

94115

Quest Clinical Research, San Francisco

98122

Swedish Medical Centre, Seattle

Unknown

Hadassah Medical Centre, Jerusalem

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Immuron Ltd.

INDUSTRY

NCT02316717 - A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter